Component
Experimental B0AT1 inhibitor from the 2026 structure-guided study
Context-specific entity; species, compartment and exposure are stated on each claim.
2 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What it acts on
Oral experimental B0AT1 inhibition increased urinary phenylalanine and lowered plasma phenylalanine in PKU-model mice.
Experimental context and source evidence
- evidence_access
- Primary abstract
- experimental_model
- PKU-model mice; oral dosing, dose not specified in accessed abstract.
- limitations
- Human efficacy and effects on other neutral amino acids are not established here.
- nutrient_topic
- L-Phenylalanine collection; species, compartment, exposure, co-substrates and manipulation remain explicit. · L-Phenylalanine
- plain_language
- A transporter intervention can lower blood levels by increasing urinary loss.
- primary_references
- Structure-guided development of a potent human B0AT1 inhibitor effective in a mouse model of phenylketonuria. · 2026 · https://pubmed.ncbi.nlm.nih.gov/42350764/ · DOI 10.1038/s42003-026-10535-y
L-Phenylalanine: transport, protein synthesis, cofactor recycling and cross-nutrient mechanisms (2026-09-19) · lines 182–188
AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text. · supports · PKU-model mice; oral dosing, dose not specified in accessed abstract. · source_derived_draft · unverified_draft
## l-phenylalanine-renal-excretion A transporter intervention can lower blood levels by increasing urinary loss. Oral experimental B0AT1 inhibition increased urinary phenylalanine and lowered plasma phenylalanine in PKU-model mice. Model: PKU-model mice; oral dosing, dose not specified in accessed abstract. Limitations: Human efficacy and effects on other neutral amino acids are not established here. Evidence access: Primary abstract Structure-guided development of a potent human B0AT1 inhibitor effective in a mouse model of phenylketonuria. · 2026 · https://pubmed.ncbi.nlm.nih.gov/42350764/ · DOI 10.1038/s42003-026-10535-y
Complete structured claim and evidenceA designed inhibitor occupied an allosteric B0AT1 pocket about 17 angstroms from the substrate site, stabilized an outward-occluded state and blocked transport with submicromolar IC50.
Experimental context and source evidence
- evidence_access
- Primary abstract
- experimental_model
- Human transporter cryo-EM and human/mouse transport inhibition assays.
- limitations
- Compound identity is not resolved in the accessed abstract; this is experimental pharmacology, not a supplement recommendation.
- nutrient_topic
- L-Phenylalanine collection; species, compartment, exposure, co-substrates and manipulation remain explicit. · L-Phenylalanine
- plain_language
- Transport can be blocked at a site away from where the amino acid binds.
- primary_references
- Structure-guided development of a potent human B0AT1 inhibitor effective in a mouse model of phenylketonuria. · 2026 · https://pubmed.ncbi.nlm.nih.gov/42350764/ · DOI 10.1038/s42003-026-10535-y
L-Phenylalanine: transport, protein synthesis, cofactor recycling and cross-nutrient mechanisms (2026-09-19) · lines 174–180
AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text. · supports · Human transporter cryo-EM and human/mouse transport inhibition assays. · source_derived_draft · unverified_draft
## l-phenylalanine-renal-inhibition Transport can be blocked at a site away from where the amino acid binds. A designed inhibitor occupied an allosteric B0AT1 pocket about 17 angstroms from the substrate site, stabilized an outward-occluded state and blocked transport with submicromolar IC50. Model: Human transporter cryo-EM and human/mouse transport inhibition assays. Limitations: Compound identity is not resolved in the accessed abstract; this is experimental pharmacology, not a supplement recommendation. Evidence access: Primary abstract Structure-guided development of a potent human B0AT1 inhibitor effective in a mouse model of phenylketonuria. · 2026 · https://pubmed.ncbi.nlm.nih.gov/42350764/ · DOI 10.1038/s42003-026-10535-y
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.